Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the companies will leverage expertise in genomics and molecular information to enhance the development of perdsonalized medicines and care for patients with cancer.
Roche Acquires Rest of Foundational Medicine for $2.4B
ليست هناك تعليقات:
إرسال تعليق